**Nocardiosis in Heart Transplant Recipients**

Michael M. Koerner MD, PhD 1, Aly El-Banayosy, MD 1, Uwe Schulz, MD 2, Mohamad Zeriouh 1, Reiner Koerfer, MD 3, PhD, Gero Tenderich, MD, PhD 3, Ali Ghodsizad, MD, PhD, FACC 4

1 Nazih Zudhi Transplant Institute / Advanced Cardiac Care INTEGRIS Baptist Medical Center, Oklshoms City

* 2 Heart and Diabetes Center Northrhine-Westphalia, Division of Heart
* Transplantation, Department of Thoracic and Cardiovascular Surgery,
* UniversityHospital of the Ruhr-University Bochum, Bad Oeynhausen, NRW,
* Germany.

3 Departmant of Heart and Vascular Surgery, Division for Surgical Therapy of End-Stage Heart Failure and Artificial Heart Support, Evangelisches und Johanniter Klinikum Niederrhein, Duisburg, NRW, Germany.

4 Heart and Vascular Institute, Penn State Milton S. Hershey Medical Center, Hershey, Pennsylvania

**Address for correspondence:**

A Ghodsizad MD, PhD, FACC, FETCS

Email address: [aghodsi@gmx.org](mailto:aghodsi@gmx.org)

Heart and Vascular Institute,

Penn State Milton S. Hershey Medical Center,

Hershey, Pennsylvania

USA

**Word Count:** 2061

**Key words:** Noccardiosis, Cardiac Transplantation, Immunosuppression, Heart failure

**Abstract**

Nocardia has emerged as an important opportunistic pathogen, especially in organ transplant recipients. Heart transplant (HT) recipients initially had an especially high rate of Nrdiosocardial infection, but this could be reduced by the routine use of cyclosportne. Our objective was to clarify the prevalence and presentation of Nocardiosis in HT recipients in a retrospective cross-sectional analysis.

**Introduction**

We are reporting on our patients, who were diagnosed with Nocardiosis after heart transplantation. Their ages at HT were 59-25 years. The onset of Nocardiosis took place between 1-4 months after transplantation respectively. The sites of illness were pleura, skin, and lung. In 2 patients, Nocardia disseminated to the brain 2-3 months after the onset of Nocardia. In all of the patients, antibiotic therapy with Imipenem/Cilastatin was effective. However, in 2 of the 3 patients, Nocardiosis recurred in the brain after the stop of antibiotic therapy. 2 patients expired in the late follow-up. The prevalence of Nocardiosis was low (0.4%), but the prognosis was poor (mortality 67%). Prolonged therapy with Imipenem/Cilastatin was recommended.

Nocardia has emerged as an important opportunistic pathogen, especially in organ transplant recipients, although it was previously a rare infection with a high mortality. Prevalence of Nocardiosis in renal transplant patients cited in the literature varies from 0% to 20% (1,2). Before the routine use of Cyclosporine, HT recipients had an especially high rate of Nocardial infection, varying from 3.1% to 37.5%, mean 13.4%. However, the routine use of Cyclosporine could reduce the incidence of Nocardiosis to between 0% and 6.3%, mean 4.5% (1, 3, 4, 5). We reviewed the records of patients with HT and proven Nocardiosis in their follow-up periods, in order to determine the prevalence and presentation of Nocardiosis at our center.

The records of 716 patients who underwent orthotopic HTs during a 7.0-year period at the Heart Center Northrhine-Westphalia, Germany were reviewed and analyzed. During this period, 727 orthotopic HTs were performed. The duration of follow-up ranged from 1 month to 7.0 years. Nocardiosis developed in 3 patients (0.4%).

The basic immunosuppressive therapy was based on double-drug therapy (Cyclosporine + Azathioprine, without the use of monoclonal or polyclonal antibodies for the induction of immunosuppressive therapy). In early postoperative terms, 4 x 250 mg Methylprednisolone were given over 3 days. Immunosuppressive therapy was intensified by pulsed steroids with 4 x 250 mg Methyl-prednisolone / 24 hours over 3 days. If there were more than 3 episodes of ongoing rejection, Prednisone (1 mg/kg/day) was given orally, and then tapered slowly to at least 0.05 mg/kg/day.

*Patient 1*

A 59-year old man underwent an orthotopic HT due to end-stage ischemic cardiomyopathy. His clinical course with immunosuppressive therapy was induced with Cyclosporine and Azathioprine alone, without steroids or antibody therapy. The postoperative course was complicated three times by rejection episodes requiring Methylprednisolone for up to one month. Prednisone was also applied. Direct microscopic examination of pleural effusion suggested Nocardia. Positive cultures on Nocardia farcinica were available on POD 163. The initial antibiotic therapy was initiated with Clavulanic acid /Amoxicillin (750 mg/day) and Ofloxacin (200 mg/day). The pleural effusion was reduced. Brain CT and MRI revealed multiple brain abscesses. Further antibiotic therapy with Amikacin (500 mg x 3/day) and Imipenem/Cilastatin (2 g x 3/day) was started and continued for 6 weeks. The condition was satisfactory with neither complication nor recurrence during the next three years.

*Patient 2*

A 62-year old man underwent an orthotopic HT due to end-stage ischemic cardiomyopathy with revascularization of the left anterior descending coronary artery and internal thoracic artery. Immunosuppressive therapy was induced with Cyclosporine and Azathioprine alone, without steroids or antibody therapy. The postoperative course was complicated more than 10 times, by rejection episodes requiring Methylprednisolone. Prednisone was required orally from POD 84. The patient developed fever, with a multiple skin abscess in his chest wall. Chest radiography revealed alveolar infiltrate in the right middle and lower lung field, which occurred due to Streptococcus ssalivarius. Antibiotic therapy with Ofloxacin (200 mg/day) and thereafter Mezclocillin (2 g x 3/day) was performed. On the other hand, a culture of purulent material in the skin abscess developed Nocardia farcinica on POD 164. The initial antibiotic therapy was started with Amikacin (500 mg x 2/day) and Imipenem/Cilastatin (2 g x 3/day) and was continued for two weeks. However, he was admitted again with high fever and a neurological disorder. Brain CT scan revealed a brain abscess near the third ventricle. The antibiotic therapy with Amikacin and Imipenem/Cilastatin was started again for 2 weeks. He died on sepsis on POD 259. On autopsy, Nocardial infection was confirmed in the skin and brain.

*Patient 3*

A 2-year old man underwent an orthotopic HT for a primitive dilated cardiomyopathy on June 7th, 1994. His clinical course is shown. Immunosuppressive therapy was induced with cyclosporine and azathioprine alone, without steroids or antibody therapy. The early postoperative course (1 month) was complicated 4 times by rejection episodes requiring Methylprednisolone, and Prednisone was required orally from the POD 6. Furthermore, renal dysfunction required hemofiltration, prolonged until 2 months after HT. On POD 36, he developed a progressive nodular non-cavitary infiltrate in the left middle lung field on chest X-ray. Antimycotic drugs (liposomal Amphotericin B (250 mg x 1/day), Flucytocin (250 mg x 2/day), and Itraconazol (100 mg/day) were given due to suspected Asperigilloma. However, on POD 93, cultures of sputum and gastric juice revealed nocardia; later Nocardia asteroids developed. He was treated with Imipenem/Cilastatin (1 g x a2/day) for 2 weeks. On the other hand,, subacute rejection, requiring not only Methylprednisolone (twice) but also rescue therapy with monoclonal antibodies (OKT3), appeared. He developed progressive liver and renal failure and thrombocytopenia. On POD 86, a rethoracotomy was performed due to hematoma. He died of multiple organ failure due to ongoing rejection on POD 118. On autopsy, lung abscess due to Nocardia disseminated to the right side.

**Discussion:**

Nocardiosis is a well-recognized complication from the immunosuppression required for transplantation. Cellular immune function is the major defense against infection, leaving transplant patients at high risk. The incidence of Nocardiosis in our HT recipients was only 0.4%. We have routinely used Cyclosporine and Azathioprine for immunosuppression, without steroids or antibody therapy. It is interesting to note that the frequency of Nocardial infection dropped threefold after Cyclosporine was used routinely for immunosuppression at other centers (3). Furthermore, we do not use monoclonal or polyclonal antibodies for the induction of immunosuppressive therapy, nor do we use steroids from the start of immunosuppressive therapy. The steroids within immunosuppressive drugs are particularly known to predispose to infections with nocardia (6). We think that the protocol described above explains the low incidence of Nocardiosis in our HT recipients. The highest incidence of Nocardial infection is in the first year after transplantation, and is often temporally related to intensive immunosuppressive therapy for rejection. The postoperative courses of our three patients with Nocardiosis were complicated by frequent rejection episodes and the need of oral steroids.

We no longer perform prophylactic therapy against Nocardial infection. However, we do believe that prophylactic therapy is necessary in patients whose clinical courses are complicated by frequent rejection episodes, as the rate of Nocardial infections has fallen in renal transplant centers using prophylactic therapy with sulfa regimens (7). In 2 patients, we experienced brain abscesses 3 months after the initial appearance of no cardial infection. We used Clavulanic acid/Amoxicillin as the initial antibiotic therapy in patient Nr.1 for 3 weeks and Amikacin and Imipenem/Cilastatin for in patient Nr.2 for 2 weeks. The central nervous system is the most frequent site of secondary involvement in disseminated infection, usually in the form of a brain abscess, which may be single or multiple. Although the efficacy of prolonged therapy has not been well documented, our results do recommend it. In immune-competent hosts with minor infections, therapy is usually given for 2 or 3 months, or at least for 6 weeks after resolution of the disease. For major infection in immunosuppressed patients, therapy should be continued for up to one year (1, 2, 8). The development of Sulfonamides provided a successful treatment of Nocardia, and they remain the mainstay of therapy. However, the concurrent administration of Cyclosporine and Trimethoprim/Sulfamethoxazole has been associated with reversible nephrotoxicity (9). Recently, Imipenem/Cilastatin seems to be a good optin, without evident side effects such as interference with the Cyclosporine (10, 11). Reduced concentration of Cyclosporine and a protective effect against Cyclosporine nephrotoxicity by Imipenem/Cilastatin have been reported in rats (12). In our HT recipients, results of disk diffusion susceptibility testing suggested that Imipenem/Cilastatin had a sufficiently high level of activity.

We experience 3 HT recipients with Nocardiosis. The prevalence of Nocardiosis in the HT recipients was low (0.4%), but the prognosis was poor. Prolonged therapy with Imipenem/Cilastatin was recommended.

**Acknowledgments**

The authors wish to thank pathologists Professor Ute Raute-Kreinsen and Professor Walter Lang for their histological and/or diagnostic support. Mrs. Sarah L. Kirkby for her linguistic and technical assistance in preparing this manuscript. Mr. Dirk Kraus and Mr. Joern Kraus for the statistical evaluations, the transplant acoordinators Mr. Herbert Gromzik and Mr. Stefan Wlost for providing the data and graphs, the Eurotransplant Foundation Leiden, The Netherlands, and all of the organized centers cooperating to share organs and donor data, the organ donors and their relatives for their gift of life. Major grant support, in providing the hard and software, was given by the German Association of Organ Recipients.

**References**

1. Chapman SW, Wilson JP. Nocardiosis in Transplant Recipients. Semin Respir Infect 1990;5:74-79.
2. [Peleg AY](http://www.ncbi.nlm.nih.gov/pubmed/?term=Peleg%20AY%5BAuthor%5D&cauthor=true&cauthor_uid=17443467)1, [Husain S](http://www.ncbi.nlm.nih.gov/pubmed/?term=Husain%20S%5BAuthor%5D&cauthor=true&cauthor_uid=17443467), [Qureshi ZA](http://www.ncbi.nlm.nih.gov/pubmed/?term=Qureshi%20ZA%5BAuthor%5D&cauthor=true&cauthor_uid=17443467) et al Risk factors, clinical characteristics, and outcome of Nocardia infection in organ transplant recipients: a matched case-control study. Clin Infect Dis. 2007 May 15;44(10):1307-14
3. Hofflin JH, Potasman I, Baldwin JC, et al. Infectious complications in heart transplant recipients receiving cyclosporine and corticosteroids. *Ann Intern Med* 1987;106:209-216.
4. Kirklin JK, Naftel DC, McGoffen, et al. Analysis of morbid events and risk factors for death after cardiac transplantation. *J Am Coll Cardiol* 19898;11:917-924.
5. Dresdale AR, Drusin RE, Lamb J, et al. Reduced infection in cardiac transplant recipients. *Circulation* (suppl II) 1985:; 72:II237-240.
6. Makay AD, Scott GM, Cohen SL, Stonehill E. Nocardia pericarditis. *BMJ* 1994;309: 1495-1497.
7. Peterson PK, Ferguson R, Fryd DS, et al. Infectious diseases in hospitalized renal transplant recipients: A prospective study of a complex and evolving problem. *Medicine* 1982;61:360-372.
8. Palmer DL, Harvey RL, Wheeler JK. Diagnostic and therapeutic considerations in Nocardia asteroids infection. *Medicine* 1974; 53:391-401.
9. Sands M, Brown RB, Interactions of cyclosporine with antimicrobial agents. *Rev Infect Dis* 1989;5:91-697.
10. Simmons BP, Gelfand MS, Robert GD. Nocardia otitidiscarviarum (Caviae) infection in a heart transplant patient presented as having a thigh abscess (Madura thigh). *J Heart Lung Transplant* 1992;11:824-826.
11. Thaler F, Gotainer B, Teodori B, Dubois C, Loriat P. Mediastinitis due to Nocardia asteroids afater cardiac transplantation. *Intensive Care Med* 1992;18:127-128.
12. Sido B, Hammer C, Mraz W, Krombach F. Nephroprotective effect of imipenem/cilastatin in reducing cyclosporine toxicity. *Transplant Proc* 1987;19:1755-1758.